| Application | Recommended Dilution |
|---|---|
| IHC | 1:50-1:200 |
DDX58, commonly known as RIG-I (retinoic acid-inducible gene I), serves as a critical cytoplasmic pattern recognition receptor that detects viral RNA and initiates innate immune responses. As a key sensor in the antiviral defense pathway, RIG-I recognizes short double-stranded RNA bearing 5'-triphosphate groups, triggering downstream signaling cascades that lead to type I interferon production and inflammatory cytokine release. This positions DDX58 as an essential target for researchers investigating viral infection mechanisms, innate immunity, and inflammatory signaling pathways.
This recombinant monoclonal antibody, clone 7F6, offers the reproducibility and consistency that demanding immunological studies require. Generated against a synthetic peptide derived from human DDX58, the antibody benefits from recombinant production technology, ensuring sequence-defined specificity and eliminating the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations. Affinity chromatography purification further enhances performance by removing non-specific immunoglobulins.
Validation in immunohistochemistry demonstrates reliable detection in paraffin-embedded human placenta tissue, with optimal staining achieved at 1:100 dilution using citrate buffer antigen retrieval at pH 6.0. This established protocol on the Leica Bond system provides researchers with a tested starting point for their own tissue studies, with a recommended working range of 1:50 to 1:200 allowing flexibility for optimization across different sample types. The antibody is also validated for ELISA applications.
Whether investigating viral sensing mechanisms, characterizing innate immune responses, or exploring DDX58's emerging roles in autoimmune conditions and cancer immunology, this antibody provides a dependable tool for advancing research in immunology and nuclear signaling pathways.
Email: support@cusabio.com
Distributors Worldwide